ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Eukaryotic Gene Expression
インパクトファクター: 1.841 5年インパクトファクター: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN 印刷: 1045-4403
ISSN オンライン: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2019030063
pages 277-285

Association of Plasma Fibrinogen Level with Insulin Resistance in Angiographically Confirmed Coronary Artery Disease Patients

Shams Tabrez
King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
Nasimudeen R. Jabir
King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
Shazi Shakil
King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia; Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
Mohammed Nabil Alama
Cardiology Unit, Department of Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia

要約

Fibrinogen is an important coagulation factor that plays a key role in thrombus formation. The co-existence of CAD, insulin resistance (IR) and coagulation incongruity are believed to exacerbate the existing condition towards more lethal pathological events.The purpose of current study was to find out a possible association between fibrinogen and IR in CAD patients. The study population consist of 135 participants; 82 angiographically confirmed CAD patients who visited the outpatient department at King Abdulaziz University Hospital (KAUH), Jeddah and 53 healthy control individuals. Peripheral blood samples were collected from CAD patients and healthy control individuals. Various biochemical parameters such as complete blood count, C-reactive protein (CRP), glycosylated hemoglobin (HbA1c), insulin, C-peptide, lipid profile, platelet, partial thromboplastin time (PTT), fibrinogen and D-dimer levels were measured by the use of different analytical methods. Calculation of homeostasis model assessment (HOMA) and non-HDL were done by using online tools. Among the studied parameters, majority of the conventional risk factors were found to be significantly increased in CAD patients compared with control individuals. Different coagulation components such as fibrinogen (223.8 vs. 394 mg/dL), D-dimer (0.25 vs. 0.63 mg/L), platelet (222.9 vs. 245.9 K/uL) and PTT (27.6 vs. 29.6 seconds) were also found to be significantly enhanced in CAD patients. Based on the severity of IR [HOMA index up to 3 and ≥ 3], comparison with different parameters such as fibrinogen, D-dimer, C-peptide and insulin in CAD groups were also made. As per HOMA index, fibrinogen level was found to be significantly increased in below and above 3 categories. Moreover, C-peptide (P < 0.01) and insulin (P < 0.001) levels also showed significant association with both HOMA groups. Our study provides an insight towards the association of fibrinogen and IR in CAD patients with respect to severity.

参考

  1. Jabir NR, Siddiqui AN, Firoz CK, Md Ashraf G, Zaidi SK, Khan MS, Shakil S, Alama MN, Kamal MA, Tabrez S. Current updates on therapeutic advances in the management of cardiovascular diseases. Curr Pharm Des. 2016;22(5):566-71.

  2. Tabrez S, Jabir NR, Firoz CK, Hindawi S, Shakil S, Damanhouri GA, Zaidi SK. Estimation of Interleukin-1p Promoter (-31 C/T and -511 T/C) Polymorphisms and Its Level in Coronary Artery Disease Patients. J Cell Biochem. 2017;118(9):2977-82.

  3. Jabir NR, Firoz CK, Kamal MA, Damanhouri GA, Alama MN, Alzahrani AS, Almehdar HA, Tabrez S. Assessment of genetic diversity in IL-6 and RANTES promoters and their level in Saudi coronary artery disease (CAD) patients. J Clin Lab Anal. 2017;31(5): e22092.

  4. Jabir NR, Firoz CK, Khan MS, Zaidi SK, Ashraf GM, Shakil S, Kamal MA, Tabrez S. Potential linkage between cerebrovascular diseases and metabolic syndrome. Curr Drug Metab. 2017;18(1):62-8.

  5. Tabrez S, Ali M, Jabir NR, Firoz CK, Ashraf GM, Hindawi S, Damanhouri GA, Nabil Alama M. A putative association of interleukin-10 promoter polymorphisms with cardiovascular disease. IUBMB Life. 2017;69(7):522-7.

  6. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453-8.

  7. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3(1):1-58.

  8. Mills JD, Grant PJ. Insulin resistance, haemostatic factors and cardiovascular risk. Br J Diabet Vasc dis. 2002;2(1):19-26.

  9. Vella CA, Burgos X, Ellis CJ, Zubia RY, Ontiveros D, Reyes H, Lozano C. Associations of insulin resistance with cardiovascular risk factors and inflammatory cytokines in normal-weight Hispanic women. Diabetes Care. 2013;36(5):1377-83.

  10. Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb Vasc Biol. 2012;32(8):1754-9.

  11. Firoz CK, Jabir NR, Khan MS, Mahmoud M, Shakil S, Damanhouri GA, Zaidi SK, Tabrez S, Kamal MA. An overview on the correlation of neurological disorders with cardiovascular disease. Saudi J Biol Sci. 2015;22(1):19-23.

  12. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metabol. 2001;86(2):713-8.

  13. Chen J, Wildman RP, Hamm LL, Muntner P, Reynolds K, Whelton PK, He J, Third National H, Nutrition Examination S. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27(12):2960-5.

  14. Arbustini E, Narula N, D'Armini AM. Fibrinogen: a circulating factor in search of its genetic architecture. Circulation. 2013;128(12):1276-80.

  15. Barazzoni R, Kiwanuka E, Zanetti M, Cristini M, Vettore M, Tessari P. Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes. Diabetes. 2003;52(7):1851-6.

  16. Klein OL, Okwuosa T, Chan C, Schreiner P, Kanaya AM, Liu K, Green D. Changes in procoagulants track longitudinally with insulin resistance: findings from the coronary artery risk development in young adults (CARDIA) study. Diabet Med. 2014;31(4):462-5.

  17. Raynaud E, Perez-Martin A, Brun J, Aissa-Benhaddad A, Fedou C, Mercier J. Relationships between fibrinogen and insulin resistance. Atherosclerosis. 2000;150(2):365-70.

  18. Kostapanos MS, Florentin M, Elisaf MS, Mikhailidis DP. Hemostatic factors and the metabolic syndrome. Curr Vasc Pharmacol. 2013;11(6):880-905.

  19. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High pre-operative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001;31(8):388-94.

  20. Banu S, Jabir NR, Manjunath NC, Firoz CK, Kamal MA, Khan MS, Tabrez S. Comparative study of non-high density lipoproteins cholesterol level and lipid profile in pre-diabetic and diabetic patients. CNS Neurol Disord Drug Targets. 2014;13(3):402-7.

  21. Hartmann M, von Birgelen C, Mintz GS, Stoel MG, Eggebrecht H, Wieneke H, Fahy M, Neumann T, van der Palen J, Louwerenburg HW, Verhorst PMJ, Erbel R. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Cardiol. 2006;48(3):446-52.

  22. Agyemang C, Born B-Jvd. Limited access to CVD medicines in low-income and middle-income countries: poverty is at the heart of the matter. The Lancet Global Health. 2018;6(3):e234-e5.

  23. Bersch-Ferreira AC, Sampaio GR, Gehringer MO, Torres EAFDS, Ross-Fernandes MB, da Silva JT, Torreglosa CR, Kovacs C, Alves R, Magnoni CD, Weber B, Rogero MM. Association between plasma fatty acids and inflammatory markers in patients with and without insulin resistance and in secondary prevention of cardiovascular disease, a cross-sectional study. Nutr J. 2018;17.

  24. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuniga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.

  25. Schnell O, Cappuccio F, Genovese S, Standl E, Valensi P, Ceriello A. Type 1 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2013;12(1):156.

  26. Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care. 2009;32(2):361-6.

  27. Ashraf GM, Greig NH, Khan TA, Hassan I, Tabrez S, Shakil S, Sheikh IA, Zaidi SK, Akram M, Jabir NR, Firoz CK, Naeem A, Alhazza IM, Damanhouri GA, Kamal MA. Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets. 2014;13(7):1280-93.

  28. Jabir NR, Kamal MA, Abuzenadah AM, Gan SH, Alama MN, Baeesa SS, Tabrez S. Alzheimer's and type 2 diabetes treatment via common enzyme targeting. CNS Neurol Disord Drug Targets. 2014;13(2):299-304.

  29. Bloomgarden ZT. World congress on insulin resistance, diabetes, and cardiovascular disease: part 1. Diabetes care. 2011;34(7):e115-20.

  30. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293-302.

  31. Banu S, Jabir NR, Manjunath NC, Khan MS, Ashraf GM, Kamal MA, Tabrez S. Reduction of post-prandial hyperglycemia by mulberry tea in type-2 diabetes patients. Saudi J Biol Sci. 2015;22(1):32-6.

  32. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus. 2011;9(2):120-38.

  33. Soma P, Pretorius E. Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14(1):96.

  34. Lima LM, Carvalho MdG, Sousa MdO. Plasminogen and fibrinogen plasma levels in coronary artery disease. Rev Bras Hematol Hemoter. 2012;34(4):298-301.

  35. Papageorgiou N, Tousoulis D, Siasos G, Stefanadis C. Is fibrinogen a marker of inflammation in coronary artery disease? Hellenic J Cardiol. 2010;51(1):1-9.

  36. Drozdz D, Lqtka M, Drozdz T, Sztefko K, Kwinta P. Thrombomodulin as a new marker of endothelial dysfunction in chronic kidney disease in children. Oxid Med Cell Longev. 2018;2018:1619293.

  37. Stulnig TM. C-reactive protein, fibrinogen, and cardiovas-cular risk. N Engl J Med. 2013;368(1):84-5.

  38. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJL, Barr ELM, Barrett-Connor E, Benjamin EJ, Bjorkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engstrom G, Folsom AR, Fowkes FGR, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jergensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CDA, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GDO, Wareham NJ, Khaw K-T, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J. C-reactive protein, fibrinogen, and c rdiovascular disease prediction. N Engl J Med. 2012;367(14):1310-20.

  39. Rana JS, Cote M, Despres JP, Sandhu MS, Talmud PJ, Ninio E, Wareham NJ, Kastelein JJP, Zwinderman AH, Khaw KT, Boekholdt SM. Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study. Heart. 2009;95(20):1682-7.

  40. Hong L-F, Li X-L, Luo S-H, Guo Y-L, Zhu C-G, Qing P, Wu N-Q, Li J-J. Association of fibrinogen with severity of stable coronary artery disease in patients with type 2 diabetic mellitus. Disease Markers. 2014;2014:485687.

  41. Peng Y, Wang H, Li Y-m, Huang B-t, Huang F-y, Xia T-l, Chai H, Wang P-j, Liu W, Zhang C, Chen M, Huang D-j. Relation between admission plasma fibrinogen levels and mortality in Chinese patients with coronary artery disease. Sci Rep. 2016;6:30506.

  42. Papageorgiou N, Briasoulis A, Hatzis G, Androulakis E, Kozanitou M, Miliou A, Charakida M, Zacharia E, Papaioannou S, Paroutoglou I, Siasos G, Pallantza Z, Tousoulis D, Papageorgiou N, Briasoulis A, Hatzis G, Androulakis E, Kozanitou M, Miliou A, Charakida M, Zacharia E, Pa- paioannou S, Paroutoglou I, Siasos G, Pallantza Z, Tou- soulis D. Coronary artery atherosclerosis in hypertensive patients: the role of fibrinogen genetic variability. Rev Esp Cardiol. 2017;70(01):34-41.

  43. Martins C, Mazza do Nascimento M, Pecoits-Filho R, Leinig C, Gonjalves LF, Fuerbringer R, Stenvinkel P, Lindholm B, Riella MC. Insulin resistance is associated with circulating fibrinogen levels in nondiabetic patients receiving peritoneal dialysis. J Ren Nutr. 2007;17(2):132-7.

  44. Sarangi R, Mahapatra S, Padhi S. Association of plasma fibrinogen and serum high-sensitivity C-reactive protein in type 2 diabetes mellitus. J Curr Res Sci Med. 2015;1(1):21.

  45. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial in-farction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994;24(7):444-53.

  46. Cavusoglu Y, Gorenek B, Alpsoy S, Unalir A, Ata N, Timuralp B. Evaluation of C-reactive protein, fibrinogen and antithrombin-III as risk factors for coronary artery disease. Isr Med Assoc J. 2001;3(1):13-6.

  47. Hartmann M, von Birgelen C, Mintz GS, Stoel MG, Eggebrecht H, Wieneke H, Fahy M, Neumann T, van der Palen J, Louwerenburg HW, Verhorst PMJ, Erbel R. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Cardiol. 2006;48(3):446-52.

  48. Banu S, Jabir NR, Manjunath CN, Shakil S, Kamal MA. C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome. CNS Neurol Disord Drug Targets. 2011;10(8):921-7.


Articles with similar content:

The Effect of Attentional Focus on Temporal-Spatial Parameters of Gait
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.22, 2010, issue 1-4
Sharon A. Nazarchuk, Nancy McNevin, Angela Hegamin, Evan T. Cohen
Patella Height in Different Ethnic Populations: An Observational Multicenter Study
Journal of Long-Term Effects of Medical Implants, Vol.29, 2019, issue 3
Stavros Angelis, Rafik Fanous, George Zoumboulis, Enrique Saavedra, Theodore Balfousias, George Zafiropoulos, Alexandros P. Apostolopoulos, Wissam Suhail Najim
Fibrin Sealant Reduces Perioperative Blood Loss in Total Hip Replacement
Journal of Long-Term Effects of Medical Implants, Vol.13, 2003, issue 5
Sandra G. Burks, Ross Crawford, Gwo-Jaw Wang, William D. Spotnitz, Charles A. Goldthwaite, Jr.
Pre- and Postnatal Toxicity of Diazinon Induces Disruption of Spermatogenetic Cell Line Evidenced by Increased Testicular Marker Enzymes Activities in Rat Offspring
Journal of Environmental Pathology, Toxicology and Oncology, Vol.32, 2013, issue 1
Srinivasa Jayachandra, Urban JA D'Souza
Immunohistochemical Profile of Tumor Pathways and Prognostic Significance in Colon Adenocarcinomas
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 1
Duygu Kösemetin, Esra Akdeniz Duran, Serkan Senol, Dincer Aydin, Metin Leblebici, Bengü Gobanoglu, Ayse Bahar Ceyran